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A B S T R A C T
The purpose of this study was to investigate the influence of the supercritical CO2 process-
ing on the particle size andmorphology of puerarin crystals.The process parameters included
solvents, temperature, pressures, antisolvent times, addition volumes, antisolvent addi-
tion rates and solute concentrations. After being processed, the dramatic reduction of the
dimensions and the change of the crystal shape were noticed. Decreasing the antisolvent
addition rate, increasing the temperature and the addition volume below 50 ml led to a de-
crease in size.The new crystal of puerarin generated at the optimal conditions was 30.34 μm.
The solvent of methanol and the concentration of 60 mg/ml were found to determine the
type and degree of crystallinity of particles. These results showed that this process has the
potential to produce a drug recrystallization product with newly generated crystal forms
and the size of drug particles could be controlled through the tuning of various experimen-
tal conditions.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-










For most orally administered poorly-soluble compounds, the
bio-absorption process is rate-limited by dissolution in gas-
trointestinal fluids; in the case of parenteral administration,
the effective bio-availability of compounds is limited by solu-
bility issues. As for the crystal drug, two key characteristics of
crystalline solid dosage forms are crystal habit and the crystal
size distribution [1].
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The conventional techniques for reduction of particle size
include mechanical comminution (through milling, crushing
and grinding), lyophilization and recrystallization of the solute
particles from solution (through solvent-antisolvent tech-
niques, spray drying and freeze-drying). All these techniques
suffer from one or more disadvantages, such as thermal and/
or chemical degradation, high solvent requirements or difficult
removal of solvent traces from the final product. Besides, the
classical crystallization techniques usually lead to a mixture
of polymorphs because of the multi-step process used.There-
fore, there is increasing interest in developing technologies
which, particularly in the case of pharmaceuticals, allow one
to produce microparticles with controlled particle size distri-
bution and product quality (crystallinity, purity, morphology)
under mild and inert conditions. Since the mid-1980s, a new
method of powder generation has appeared involving crystal-
lization with supercritical fluids. CO2 is the most widely used
solvent and its innocuity and “green” characteristics make it
the best candidate for the pharmaceutical industry. Supercritical
fluid technology, particularly when using CO2, offers different
possibilities to tackle the above-mentioned challenges [2,3].And
it is also interesting to check if the supercritical crystalliza-
tion (a single-step unit) may give different results.These include
the processes called rapid expansion of supercritical solu-
tions (RESS), precipitation with compressed antisolvent (PCA,
sometimes referred to as SAS, i.e., supercritical antisolvent
process, or ASES, i.e., aerosol spray extraction system) and gas
antisolvent recrystallization (GAS) [4–7]. In the GAS process,
high pressure CO2 is injected into the liquid phase solution,
which causes a sharp reduction of the solute solubility in the
expanded liquid phase. As a result, precipitation of the dis-
solved compound occurs.The potential advantages of the GAS
recrystallization process lie in the possibility of obtainingmicron
and submicron particles with a narrow size distribution and
lower residual solvent. By varying the process parameters, the
particle size, size distribution and morphology can be “tuned”
to produce a product with desirable qualities. This makes the
GAS technique attractive for the micronization of high-
valued products such as pharmaceuticals [8,9].
Adopting a GAS process to recrystallize pharmaceutical
compounds will provide highly versatile methodology to
generate new polymorphs of drugs. Many researchers have
employed the GAS process for micronization and recrystalli-
zation of various pharmaceutical substances [10–12]. They
have concentrated on the size reduction of pharmaceutical
compounds and they observed changes in the external shape
and size distribution of the resulting particles. The diversity
of experimental parameters of the GAS process can vary the
conditions for nucleation and crystal growth steps in a wide
range. It is possible to produce drug particles with different
crystalline arrangements but identical chemical composi-
tions. Such behavior is called polymorphism, meaning the
ability of any compound to crystallize into more than one
distinct crystalline state [13]. This can be important to the
quality of a given product. In the pharmaceutical field, an
active substance may exhibit different activities and shelf
life depending on the polymorph. Properties such as solubil-
ity, dissolution rate, density, physical stability and melting
point change depending on the type of crystalline forms.
Therefore, the various polymorphs of a given pharmaceutical
compound will exhibit different drug release characteristics
and biological activity.
With the application of modern isolation technology and
high throughput biological screen capability, more and more
natural compounds with biological activity are being isolated
and identified. However,many of these compounds with potent
activity in vitro fail to generate good activity in vivo owing to
their poor water-solubility, poor permeability and/or poor sta-
bility [14]. Puerarin (Pur) was such a drug, chemically designated
as 8-C-β-D-Glucopyranosyl-4′, 7-hydroxy-Isoflavone, and was
one of themain active constituents of Pueraria lobata (wild.) ohwi,
a famous Chinese traditional medicine. Pur has many types
of beneficial effects on cardiovascular, neurological and hy-
perglycemic disorders. However, its poor solubility in water
limits its absorption in vivo [15–17]. Solubilizer is often added
to the injection formulation used clinically to increase its solu-
bility. Research on the polymorphism of Pur was quite few.There
was only related literature which reported that Pur did have
various crystalline forms depending on experimental condi-
tions adopted in the conventional solution crystallization
techniques [18]. The objective of this research was to investi-
gate the feasibility of the GAS recrystallization technique to
generate small particles of Pur with a high degree of purity and
narrow size distribution. By surveying the production of dif-
ferent crystalline forms of Pur using the GAS process, we
focused on how the solid-state properties of the recrystal-
lized particles including particle size, morphology and crystal
form varied with the process parameters such as the antisolvent
addition rates, the pressures, the addition volumes, the con-
centrations, the antisolvent times, the types of solvent and
temperatures.And we hope to find new polymorphs with better
physico-chemical properties such as higher solubilities, dis-
solution rate and smaller particle size. The newly generated
polymorph of Pur could be used for the injection or oral for-
mulation with better bioactivity. So, here we recrystallized Pur
by using CO2 as an antisolvent and examined the character-
istics of the GAS processed crystals by using various analytical
instruments.
2. Materials and methods
2.1. Materials
Absolute ethanol, acetone andmethanol, analytical grade, purity
of 99.7%, were bought from Guangzhou Chemical Reagent 2
Factory (Guangzhou, China). Pur, purity of 99.9%, was ob-
tained from Beijing Union Pharmaceutical Factory (Beijing,
China). Liquid CO2, instrument grade, purity of 99.5%, was pur-
chased from Zhonghong Industrial Gas (Shenzhen) Co. Ltd.
(Shenzhen, China).
2.2. Experimental procedure
A schematic diagram of the GAS apparatus is shown in a pre-
vious paper [19]. The unit consists of three sections: a CO2
supplying system controlled by Isco Series D pump power con-
troller (Teledyne Isco, Inc., Lincoln, NE), a crystallizing chamber
(Thar Designs Inc., Pittsburgh, PA), and a depressurizing section.
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The temperature of the vessel was maintained in an Athena
heater (Model 2000-B, Athena Controls, Inc., Plymouth Meeting,
PA). In the batch GAS step configuration, the precipitation unit
was initially loaded with a volume of Pur solution. Then CO2
was added until the final pressure was reached.The rate of CO2
addition is 75 ml/min. The volume of the precipitation vessel
was 250 ml.The vessel was filled with CO2 at the desired tem-
perature and left for 3 h without any agitation. A pure constant
CO2 flow rate of 25 ml/min was then maintained in order to
completely remove the residual solvent.After this washing step
which lasted for approximately 90 min, the autoclave was de-
pressurized for 30 min at the experimental temperature. Finally,
the dry solid powder was collected for off-line analysis.
GAS experiments were carried out with the following ex-
perimental conditions range: recrystallization temperature of
30–43 °C, recrystallization pressure of 8–14 MPa, Pur solute con-
centration of 60–120 mg/ml, solution addition volume of 10–
100 ml, antisolvent time of 1–6 h, type of solvent of absolute
methanol, absolute ethanol and acetone, antisolvent addi-
tion rate of 25–105 ml/min.
2.3. Powder morphology
Samples of the processed powder were observed by scanning
electron microscopy (SEM; Jeol JSM-6460LV, Japan). Powder
samples were manually dispersed on an aluminum stub with
a thin self-adhered carbon film.The samples were coated with
a thin layer of gold using an ion sputter under 0.5 mbar argon
atmosphere (at room temperature for 90 s, at an accelerating
voltage of 20 kV, working distance of 15 mm, and at 1000, 3000
and 5000 magnification).
2.4. Particle size distribution
Particle size distribution (PSD) was measured by laser diffrac-
tion using Master size 2000 laser particle analyzer (Malvern
Instruments Ltd., Malvern, UK). The method used for analy-
sis was dry method.
3. Results and discussion
The detailed operating conditions and the particle size results
of the GAS recrystallization experimental runs are reported in
Table 1. The recrystallization of Pur was performed by chang-
ing several experimental variables of the GAS process as shown
in the above range. Of all the variables, the type of solvent most
strongly affected the crystal form and morphology. The tem-
perature, addition volume and antisolvent addition rate most
strongly affected the particle size. The reproducibility of the
experimental results had been duly checked. A good repro-
ducibility of the obtained particle size and size distribution was
observed. In general, average measured yields from experi-
ments were determined to be above 90%.The trends in particle
size and shape from manipulation of these variables were dis-
cussed below accordingly.
3.1. Effect of the recrystallization pressure
Several experiments were conducted in the pressure range of
8–14 MPa, with the other operating conditions maintaining at
the temperature of 38 °C, antisolvent addition rate of 75 ml/
min, Pur concentration of 100 mg/ml, solvent of absolute
ethanol, antisolvent time of 3 h and addition volume of 50 ml.
When the pressure was increased from 8 MPa to 14 MPa, the
particle size of Pur is increased (Fig. 1A). It was reported that
when pressure was high, it was in favor of nucleation, which
created a lot of nucleus and thus we obtained crystals with
smaller size [13].When the pressure was low, the solvent was
not fully expanded,more solvent existed between particles, and
the crystal’s growth time was prolonged and larger particles

















1 8 38 100 75 50 3 EtOH 35.69 ± 2.33
2 12 38 100 75 50 3 EtOH 38.21 ± 5.98
3 14 38 100 75 50 3 EtOH 39.35 ± 3.55
4 10 38 80 75 50 3 EtOH 37.36 ± 4.67
5 10 38 60 75 50 3 EtOH 38.15 ± 4.54
6 10 38 120 75 50 3 EtOH 30.97 ± 3.89
7 10 33 100 75 50 3 EtOH 39.79 ± 6.52
8 10 43 100 75 50 3 EtOH 29.70 ± 4.21
9 10 38 100 75 50 3 EtOH 30.34 ± 5.18
10 10 38 100 75 50 1 EtOH 33.27 ± 7.16
11 10 38 100 75 50 6 EtOH 37.97 ± 5.64
12 10 38 100 75 10 3 EtOH 43.83 ± 7.71
13 10 38 100 75 25 3 EtOH 43.69 ± 8.23
14 10 38 100 75 100 3 EtOH 51.12 ± 6.19
15 10 38 100 75 50 3 MeOH 47.65 ± 4.97
16 10 38 100 75 50 3 Ace 39.52 ± 5.35
17 10 38 100 25 50 3 EtOH 31.22 ± 3.77
18 10 38 100 105 50 3 EtOH 49.26 ± 6.24
a The antisolvent addition rate.
b The addition volume of puerarin solution.
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Fig. 1 – Effect of various conditions on the particle size of puerarin in GAS process. Pressures (A), temperatures (B),
concentrations (C), antisolvent times (D), addition volumes (E), antisolvent addition rates (F) and solvents (G) were
compared.
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were obtained. In our investigation, the higher the pressure,
the stronger the dissolving abilities of supercritical CO2 to
ethanol and thus the higher degree of supersaturation. A large
amount of micronuclei is precipitated instantaneously, and con-
glutination between particles may lead to the increased particle
size. The variation of pressure is directly related to the rate of
nucleation and crystal growth and may result in a different
crystal molecular arrangement. Yet in our research, the pres-
sure appeared to have little effect on the particle shape of Pur,
which all exhibited as needle-like crystals as shown in Fig. 2.
When the pressure was increased to 14 MPa, the increased solu-
bility of Pur in the supercritical solution and the decreased
supersaturation lead to more needle crystals and the particle
size is increased accordingly.
3.2. Effect of the recrystallization temperature
Experiments were performed at fixed conditions as men-
tioned above while varying the temperatures only.As illustrated
in Fig. 1B, an increase in the process temperature (33, 38, and
43 °C) for the recrystallization process resulted in a direct de-
crease of the Pur particle size and a narrowing of the size
distribution. The particle size is similar at 38 °C and 43 °C,
but it is increased tremendously at 33 °C. Temperature has
two different effects on the particle size. On the one hand,
higher temperature promotes themass transfer between solvent
and supercritical CO2 which favor the formation of high su-
persaturation and smaller particles are prepared. On the other
hand, higher temperature leads to the reduction of CO2 density
and the reduction of the dissolving ability for solvent. Thus
supersaturation is decreased and bigger particles are formed.
High temperature would also accelerate the molecular motion
that favors the particles aggregation. Finally, the above
positive and negative impacts determine the formation of
particles [20]. Besides, the crystallization temperature has prac-
tically no effect on the crystal habit of Pur within the
temperature range investigated. Pur crystal particles pre-
pared at different temperatures are mainly characterized by
prismatic crystals with needle-like structures which are almost
the same (Fig. 3).
3.3. Effect of the Pur solution concentration
We varied the concentrations of Pur ethanol solution from 60
to 120 mg/ml while maintaining other process parameters.The
results showed that an increase in Pur concentration gave a
decrease in particle size, then a little increase at Pur concen-
trations above 100 mg/ml (Fig. 1C). This could be explained by
a combined effect of two factors in terms of nucleation and
growth of particles. It is commonly admitted that increasing
the solute concentration results in larger particles and en-
larged PSD. At higher solute concentrations, precipitation of
the solute occurs earlier in time during the expansion process,
resulting in increased time for crystal growth. At lower solute
concentrations, precipitation of the solute is reached later during
the expansion process; hence, nucleation is the prevailing
mechanism giving smaller particles [8]. In our research we noted
that the smallest particle size was got in the middle of the con-
centration range. Firstly, at concentrations below 100 mg/ml,
supersaturation is increased with the increase of the solute con-
centration, and the primary nuclei size would diminish to the
smallest at 100 mg/ml; then, when the concentration was above
100 mg/ml, high solute concentrations produced more aggre-
gated particles.The higher the nuclei concentration, the higher
the interaction between particles formed. Particles agglomer-
ate at high Pur concentrations and PSD is broadened. Different
Fig. 2 – SEM micrographs of Pur precipitated with different pressure: (A) 8 MPa, (B) 10 MPa, (C) 12 MPa and (D) 14 MPa.
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Pur concentrations in the GAS process produced particles with
similar morphology (Fig. 4). Low solute concentrations produce
long prism crystals not very uniformly while high concentra-
tions favor the uniform particle appearances and the length
of prisms shortens. Because of dilute solutions, low super-
saturation is produced and less particles are formed.The growth
mode of particles dominates and long prism-like structure is
obtained.
3.4. Effect of the antisolvent time
It was reported that in the GAS process the solute
crystallized more often in a supercritical mixture of CO2 and
solvent.The antisolvent time in this mixture may induce trans-
formations as dissolution–recrystallization, solid/solid transition,
etc. Therefore, the antisolvent time of the powder in crystal-
lization vessel may be an important parameter for the
Fig. 3 – SEM micrographs of Pur precipitated with different temperature: (A) 33 °C, (B) 38 °C and (C) 43 °C.
Fig. 4 – SEM micrographs of Pur precipitated with different Pur concentration: (A) 60 mg/ml, (B) 80 mg/ml, (C) 100 mg/ml and
(D) 120 mg/ml.
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morphology of the powder finally obtained (polymorphism,
aggregation . . .) [21]. In our research, the results of particle size
showed that too short and too long antisolvent time all led to
the increase of particle size (Fig. 1D). The extension of
antisolvent time has a negative influence on the decrease of
particle size when a certain time has reached. 3 h is enough
for the shortening of experiment time.Yet the antisolvent time
has no effect on the particle morphology (Fig. 5).
3.5. Effect of the addition volume
Experiments were performed at fixed conditions as men-
tioned above while varying the addition volume in the
precipitation vessel between 10, 25, 50 and 100 ml. The effect
of this process parameter was not investigated in previous
similar researches. From our results, it should be noted that
the initial addition of volume in the precipitation vessel does
have effect on the particle size of Pur crystals. When the so-
lution was less than 50 ml in volume, the larger the volume,
the smaller the particle size (Fig. 1E). The PSD is narrowest at
the lowest volume of 10 ml, but the size is biggest, a really
strange phenomenon.When the solution volume was 100 ml,
the largest particle size and the widest PSD of Pur crystals are
obtained. The volume expansion rate is high when the initial
solution volume is small.Thus a large number of particles were
precipitated and collided into bigger particles while the PSD
was uniform.When the volume was 100 ml, the precipitation
vessel was relatively overloaded, and the expansion rate of
volume was pretty low. Few particles were produced and the
growth dominated over nucleation, so the largest particles were
got. The SEM picture indicated that there was no difference
between particles morphology at different solution volumes
(Fig. 6), but it was clear that the particle size distribution went
to a relatively wide range. Because a high solution volume im-
plicated a lower supersaturation and bigger particles were
produced, some small ones were also produced. And thus a
wide distribution was achieved.
3.6. Effect of the antisolvent addition rate
First, let us focus on the experiment runs numbered 17, 9 and
18 in Table 1, which have been performed at increasing values
of the antisolvent addition rate. Pur crystal microparticles
formed at 25 ml/min and 75 ml/min had similar size, while par-
ticles generated at 105 ml/min had much bigger ones (Fig. 1F).
The various process parameters of the GAS process such as
the type of solvent, crystallizing temperature, and antisolvent
injection rate clearly affected the solid-state characteristics of
particular hydrophobic drug particles [22]. The magnitude of
the supersaturation level is a strong function of the applied
volumetric expansion rate. A faster rate of antisolvent addi-
tion will generate higher levels of supersaturation, thus, higher
rates of nucleation, and consequently, a larger number of
smaller size particles with narrow particle size distribution. Op-
positely, low addition rates caused both nucleation and crystal
growth. The competition between the nucleation and growth
dynamics of the GAS process needs to be considered to explain
the bigger particles formed at lower pressure addition rates [23].
Our contrary experimental results with GAS micronization of
Pur particles indicated that during the rapid pressure increas-
ing process at 105 ml/min of antisolvent addition rate, the
solution may achieve supersaturation locally and some crystal
nuclei were formed firstly, thus the particle size distribution
was uneven and bigger particles were obtained since the con-
sumption of the solute mainly depended on the growth of the
nuclei. SEM photomicrograph showed that the crystal habit
changed a little bit at different antisolvent addition rates (Fig. 7).
The slowest rate resulted in regular short prisms and the fastest
Fig. 5 – SEM micrographs of Pur precipitated with different residence time: (A) 1 h, (B) 3 h and (C) 6 h.
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rate produced both prism-like and needle-like crystal mor-
phology with obvious increase in the particle size.The two kinds
of particles morphology produced at the highest rate of pres-
sure stemmed from the local expansion in the solution and
different growth rates of the crystal surfaces of a single crystal
[19]. To go into more details, a remarkable reduction of the
crystal dimensions with a restricted particle size distribution
was obtained at 25 and 75 ml/min of antisolvent addition rates,
with 75 ml/min seemingly being the most efficient rate to mi-
cronize this drug as a whole.
3.7. Effect of the solvent
The effect of solvent on determining the crystal growth mecha-
nism in liquid crystallization is a subject of extensive research.
The degree of crystallinity of the formed particles is
Fig. 6 – SEM micrographs of Pur precipitated with different addition volume: (A) 10 ml, (B) 25 ml, (C) 50 ml and (D) 100 ml.
Fig. 7 – SEM micrographs of Pur precipitated with different antisolvent addition rate: (A) 25 ml/min, (B) 75 ml/min and (C)
105 ml/min.
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important for processing pharmaceuticals, as it sheds some
light on the role of the solvent during particle growth. To in-
vestigate the influence of the solvent on Pur crystallinity, the
effect of the organic solvents, methanol and acetone were
studied in addition to ethanol. The results showed that com-
pared with other process parameters, the type of solvent had
a dramatic effect on particle size, the external shape and in-
ternal characteristics of crystals as reported in other researches
[6,24]. The particle size was smallest with ethanol as solvent
and the size was biggest with methanol as solvent (Fig. 1G).
This result encouraged investigating the influence of sol-
vents on the physicochemical properties of pharmaceutical
compounds in our future studies.
The precipitation of Pur from ethanol and methanol gave
a very light, voluminous powder, as typical of CO2-precipitated
samples showing long prisms and needle morphology in SEM
pictures (Fig. 8A and B) which was consistent with the re-
search of Moneghini et al. [25], whilst the gross morphology
of sample treated with acetone was less voluminous and char-
acterized by the presence of long needles with brushes (Fig. 8C).
The variation of solvent to acetone resulted in a modification
of the crystal habit of Pur. But whatever the solvent used, Pur
produced by GAS was all a crystalline product, contrary to what
happened in the case of SEDS (Solution Enhanced Dispersion
by Supercritical Fluid) method where amorphousmicroparticles
have been obtained [26].Though the external shape of Pur crys-
tals was different in acetone, the crystal pattern was the same
with Pur obtained in ethanol which was identified and pub-
lished in another paper by the confirmation of a series of
characteristic analysis [27]. It was known that inclusion of
solvent molecules in the solid lattice and/or interaction of the
solvent with the growing crystal surface may drastically change
crystal morphology.Therefore, the results obtained in these ex-
periments were not surprising even if it was rather difficult
to explain and predict them.
Generally, Pur recrystallization by GAS in this experiment
all reproducibly yielded a crystalline product at each condi-
tion. At most conditions, Pur produced was in the same crystal
form (named crystal form II), while with 60 mg/ml as the Pur
concentration (crystal form III) and with methanol as solvent
(crystal form IV), Pur in two new crystal forms was achieved.
The confirmation of the new crystal forms was published in
another paper [27].The GAS processed crystals in three crystal
forms all showed more ordered appearances with clean sur-
faces and sharp angles compared with the unprocessed particles
(Fig. 9) and there was only one pure crystal produced at each
Fig. 8 – SEM micrographs of Pur precipitated with different solvent: (A) Methanol, (B) Ethanol and (C) Acetone.
Fig. 9 – SEM micrograph of commercial Pur.
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experimental condition.Various general studies on the recrys-
tallization of drug by GAS method also indicated a change in
particle morphology [28,29]. Besides the newly generated crystal
form, the effects of various process conditions on Pur crys-
tals were mainly investigated. From the particle size results,
the optimized process conditions for Pur in crystal form II were:
pressure of 10 MPa, temperature of 38 °C, antisolvent
addition rate of 75 ml/min, Pur concentration of 100 mg/ml,
antisolvent time of 3 h, solvent of ethanol and addition volume
of 50 ml. Under these conditions, Pur crystals with the average
size of 30.34 μm were obtained. Compared with the commer-
cial Pur sized 45.34 μm, Pur recrystallized by GAS in crystal form
II reduced the particle size dramatically, thus this may facili-
tate its dissolution rate and further enhance the bioavailability
which should be confirmed in future research.
4. Conclusion
In this study, the GAS crystallization technique has been applied
to the preparation of Pur. To sum up, it was clear that several
parameters had an influence on the size and morphology of
the crystals obtained and it was demonstrated that the par-
ticles’ mean diameter and size distribution can be strongly
controlled through the manipulation of the process param-
eters in GAS process. Of all process parameters, a good choice
of the solute concentration and the solvent may lead to new
pure polymorphs, while temperature, addition volume, and
antisolvent addition rate had many influences on the par-
ticle size and size distribution. It must be pointed out that the
analysis of morphology and the size of the drug showed a dra-
matic change of the crystals after treatment with supercritical
fluids, indicating the formation of a light voluminous powder
made of small particles having needle-like and prism habit.
The GAS recrystallization process may provide an entirely dif-
ferent concept and kinetics for nucleation and molecular
arrangement. Therefore, adopting a GAS process to recrystal-
lize pharmaceutical compounds will provide a highly versatile
methodology to generate new polymorphs of the drug in ad-
dition to conventional crystallization techniques and provide
the potential for better therapeutic efficacy of the drug because
of the newly generated crystal form.
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